journal
Journals Seminars in Interventional Rad...

Seminars in Interventional Radiology

https://read.qxmd.com/read/38495267/practical-considerations-when-choosing-chemoembolization-versus-radioembolization-for-hepatocellular-carcinoma
#1
REVIEW
Ashkan Heshmatzadeh Behzadi, Leila Haghani, Donna L D'Souza, Siobhan Flanagan, Christopher Jones
Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) are common liver-directed therapies (LDTs) for unresectable HCC. While both deliver intra-arterial treatment directly to the site of the tumor, they differ in mechanisms of action and side effects. Several studies have compared their side effect profile, time to progression, and overall survival data, but often these lack practical considerations when choosing which treatment modality to use. Many factors can impact operator's choice for treatment, and the choice depends on treatment availability, cost, insurance coverage, operator's comfort level, patient-specific factors, tumor location, tumor biology, and disease stage...
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495266/immunoembolization-for-the-treatment-of-uveal-melanoma-hepatic-metastases
#2
REVIEW
Carin F Gonsalves
Uveal melanoma is the most common primary intraocular tumor in adults. Approximately 50% of patients develop metastatic disease despite successful treatment of the primary eye tumor. The liver is the most common site of metastatic disease occurring in more than 90% of patients. Clinical prognosis is dependent on the ability to control the growth of liver tumors. Locoregional therapies play an important role in stabilizing liver metastases, prolonging survival for patients with metastatic uveal melanoma. As overall survival is prolonged, the development of extrahepatic disease becomes more common...
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495265/a-simple-involute-technique-for-successful-removal-of-a-caudally-migrated-viatorr-stent-graft
#3
REVIEW
Vellia Zhou, Mark Reddick, Daniel Lamus, Ronald S Arellano, Sanjeeva P Kalva
No abstract text is available yet for this article.
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495264/techniques-to-optimize-radioembolization-tumor-coverage
#4
REVIEW
M Kasim Fassia, Resmi Ann Charalel
Yttrium-90 (Y90) radioembolization has become a major locoregional treatment option for several primary and secondary liver cancers. Understanding the various factors that contribute to optimal tumor coverage including sphere count, embolization techniques, and catheter choice is important for all interventional radiologists while planning Y90 dosimetry and delivery. Here, we review these factors and the evidence supporting current practice paradigms.
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495263/chemoembolization-beyond-hepatocellular-carcinoma-what-tumors-can-we-treat-and-when
#5
REVIEW
Daniel M DePietro, Xin Li, Susan M Shamimi-Noori
Liver metastases are the most common malignancy found in the liver and are 20 to 40 times more common than primary hepatic tumors, including hepatocellular carcinoma. Patients with liver metastases often present with advanced disease and are not eligible for curative-intent surgery or ablative techniques. The unique hepatic arterial blood supply of liver metastases allows interventional radiologists to target these tumors with transarterial therapies. Transarterial chemoembolization (TACE) has been studied in the treatment of liver metastases originating from a variety of primary malignancies and has demonstrated benefits in terms of hepatic progression-free survival, overall survival, and symptomatic relief, among other benefits...
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495262/advanced-imaging-techniques-used-in-direct-portosystemic-shunt-creation-in-budd-chiari-syndrome-with-complex-venous-anatomy
#6
REVIEW
Sara Rostami, Jaclyn Fickert, Connor Morris, Michael Samuel, Doan Vu, Charles E Ray, Ali Kord
No abstract text is available yet for this article.
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495261/intra-arterial-peptide-receptor-radionuclide-therapy-for-the-treatment-of-hepatic-neuroendocrine-tumor-metastases-hope-or-hype
#7
REVIEW
Michael V Khanjyan, Nicholas Fidelman
Peptide receptor radionuclide therapy (PRRT) confers significant progression-free survival advantage for patients with small bowel grade 1 and 2 well-differentiated neuroendocrine tumors (WD NET). PRRT may also be clinically beneficial for patients with NET of pancreatic, bronchial, and other sites of origin; patients with paragangliomas; as well as for patients with well-differentiated grade 3 NET. Direct intra-arterial (IA) administration of PRRT into the hepatic artery for patients with NET liver metastases may result in higher radiopharmaceutical dose and longer dwell time in the liver tumors while relatively sparing non-tumor liver tissue and other organs such as the kidneys and bone marrow when compared with intravenous (IV) administration...
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495260/embolic-agents-sclerotherapy
#8
REVIEW
Christina Lim, Sean Lee, Abheek Ghosh, Brian Funaki
No abstract text is available yet for this article.
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495259/sbrt-for-liver-tumors-what-the-interventional-radiologist-needs-to-know
#9
REVIEW
Michael J Gutman, Lucas M Serra, Matthew Koshy, Rohan R Katipally
This review summarizes the clinical evidence supporting the utilization of stereotactic body radiotherapy (SBRT) for liver tumors, including hepatocellular carcinoma, liver metastases, and cholangiocarcinoma. Emerging prospective evidence has demonstrated the benefit and low rates of toxicity across a broad range of clinical contexts. We provide an introduction for the interventional radiologist, with a discussion of underlying themes such as tumor dose-response, mitigation of liver toxicity, and the technical considerations relevant to performing liver SBRT...
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495258/hepatocellular-carcinoma-advances-in-systemic-therapy
#10
REVIEW
Insija Ilyas Selene, Merve Ozen, Reema A Patel
Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death. This article reviews the evolving landscape of systemic therapies for advanced HCC, emphasizing recent advancements and their impact on patient outcomes. The advent of molecular targeted therapies has transformed HCC management, with sorafenib being the first FDA-approved molecular targeted therapy, setting a standard for a decade. However, recent breakthroughs involve the combination of atezolizumab and bevacizumab, demonstrating superior outcomes over sorafenib, leading to FDA approval in 2020...
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495257/yttrium-90-radioembolization-dosimetry-dose-considerations-optimization-and-tips
#11
REVIEW
Alexander Villalobos, Johannes L du Pisanie, Ripal T Gandhi, Nima Kokabi
No abstract text is available yet for this article.
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38495256/biologics-immunotherapies-and-cytotoxic-chemotherapy-for-hepatocellular-carcinoma-following-current-recommendations-by-the-bclc-a-review-of-agents
#12
REVIEW
Rajangad S Gurtatta, Sydney E Whalen, Charles E Ray
No abstract text is available yet for this article.
February 2024: Seminars in Interventional Radiology
https://read.qxmd.com/read/38274223/a-review-of-resection-and-surgical-ablation-for-primary-and-secondary-liver-cancers
#13
REVIEW
McKenzie J White, Eric H Jensen, David G Brauer
The surgical management of primary and secondary liver tumors is constantly evolving. Patient selection, particularly with regard to determining resectability, is vital to the success of programs directed toward invasive treatments of liver tumors. Particular attention should be paid toward determining whether patients are best served with surgical resection or ablative therapies. A multidisciplinary approach is necessary to provide optimal care to patients with liver malignancy.
December 2023: Seminars in Interventional Radiology
https://read.qxmd.com/read/38274222/liver-directed-therapy-combined-with-systemic-therapy-current-status-and-future-directions
#14
REVIEW
Shamar Young, Jack Hannallah, Dan Goldberg, Mohammad Khreiss, Rachna Shroff, Junaid Arshad, Aaron Scott, Gregory Woodhead
In the past several decades, major advances in both systemic and locoregional therapies have been made for many cancer patients. This has led to modern cancer treatment algorithms frequently calling for active interventions by multiple subspecialists at the same time. One of the areas where this can be clearly seen is the concomitant use of locoregional and systemic therapies in patients with primary or secondary cancers of the liver. These combined algorithms have gained favor over the last decade and are largely focused on the allure of the combined ability to control systemic disease while at the same time addressing refractory/resistant clonal populations...
December 2023: Seminars in Interventional Radiology
https://read.qxmd.com/read/38274221/ablation-versus-radiation-segmentectomy-for-small-liver-tumors
#15
REVIEW
Merve Ozen, Ronak K Patel
Hepatocellular carcinoma (HCC) is a liver malignancy that affects more than a million people worldwide with a complex multifactorial etiology. After the diagnosis of HCC is made, physicians establish management using the Barcelona Clinic Liver Cancer (BCLC) guidelines revolving around tumor stage, liver function, performance status, and patient preferences. According to recent updates to these guidelines, thermal ablation is the second-best curative option apart from surgical resection for small HCC (< 2 cm)...
December 2023: Seminars in Interventional Radiology
https://read.qxmd.com/read/38274220/thermal-ablation-in-the-liver-heat-versus-cold-what-is-the-role-of-cryoablation
#16
REVIEW
Donna L D'Souza, Ranjan Ragulojan, Chunxiao Guo, Connie M Dale, Christopher J Jones, Reza Talaie
Cryoablation is commonly used in the kidney, lung, breast, and soft tissue, but is an uncommon choice in the liver where radiofrequency ablation (RFA) and microwave ablation (MWA) predominate. This is in part for historical reasons due to serious complications that occurred with open hepatic cryoablation using early technology. More current technology combined with image-guided percutaneous approaches has ameliorated these issues and allowed cryoablation to become a safe and effective thermal ablation modality for treating liver tumors...
December 2023: Seminars in Interventional Radiology
https://read.qxmd.com/read/38274219/chemoembolization-plus-ablation-current-status
#17
REVIEW
Farnaz Dadrass, Pascal Acree, Edward Kim
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. The treatment landscape for HCC has evolved significantly over the past decade, with several modalities available to treat various stages of disease. The Barcelona Clinic Liver Cancer (BCLC) system provides a foundation for treatment guidance. However, given the complex nature of HCC, a more nuanced approach is often required, especially for lesions sized between 3 and 5 cm. This review aims to analyze the available treatments for early-stage HCC lesions between 3 and 5 cm, with a focus on the therapeutic potential and efficacy of transarterial chemoembolization (TACE)-ablation...
December 2023: Seminars in Interventional Radiology
https://read.qxmd.com/read/38274218/hepatocellular-carcinoma-from-a-hepatologist-s-perspective
#18
REVIEW
Giovanni A Roldan, Jacquelin Blomker, Elizabeth S Aby
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, represents a growing health challenge worldwide. The incidence of HCC is rising, which, in turn, has led to a corresponding increase in the associated number of deaths. HCC will become the third leading cause of cancer-related deaths in the United States by 2030. HCC usually develops in the setting of chronic liver disease. Individuals at increased risk of HCC are recommended to undergo surveillance with ultrasound every 6 months along with serum α-fetoprotein testing...
December 2023: Seminars in Interventional Radiology
https://read.qxmd.com/read/38274217/intravascular-ultrasound-guided-retrieval-of-a-radiolucent-foreign-body-from-the-superior-vena-cava
#19
REVIEW
Sara Rostami, Jacob Miller, Nikhil Grandhi, Charles E Ray, Ali Kord
No abstract text is available yet for this article.
December 2023: Seminars in Interventional Radiology
https://read.qxmd.com/read/38274216/non-thermal-liver-ablation-existing-and-new-technology
#20
REVIEW
Tiffany Nakla, Jacqueline J Chow, Kathleen Pham, Nadine Abi-Jaoudeh
Cancer has and continues to be a complex health crisis plaguing millions around the world. Alcohol ablation was one of the initial methods used for the treatment of liver lesions. It was surpassed by thermal ablation which has played a big role in the therapeutic arsenal for primary and metastatic liver tumors. However, thermal ablation has several shortcomings and limitations that prompted the development of alternative technologies including electroporation and histotripsy. Percutaneous alcohol injection in the liver lesion leads to dehydration and coagulative necrosis...
December 2023: Seminars in Interventional Radiology
journal
journal
29165
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.